Sanofi-Aventis and Regeneron Pharmaceuticals Inc. have expanded an existing development partnership to run through 2017.
People looking for natural cures will be happy to know there is one. Two words explain how it works: "I believe." It's the placebo effect - the ability of a dummy pill or a faked treatment to make people feel better, just because they expect that it will.
Netherlands based diagnostic products maker Qiagen NV is buying privately held diagnostic test maker SABiosciences Corp. for about $90 million in cash.
Bristol-Myers Squibb Co. and Alder Biopharmaceuticals Inc. said they signed a collaboration deal potentially worth $1 billion, with a key focus on a rheumatoid arthritis treatment.
Hollow fiber bioreactor cartridges from FiberCell Systems Inc. offer a simple two-compartment set-up for in vitro toxicology with higher levels of reproducible control of complex growth, infection, treatment, and sampling regimens.
Thermo Fisher Scientific announces the availability of dual-sparge technology for Thermo Scientific HyClone Single-Use Bioreactor (S.U.B.) system.
The Automation Partnership (TAP), a leader in the design and development of innovative automation for life science applications, is previewing its Advanced Microscale BioReactor (ambr) technology at the Bioprocess International Conference.
Pfizer Inc announced its global research and development network, marking an important step in implementing a new R&D model as part of the integration of Pfizer and Wyeth.
A compound already used to treat pneumonia could become a new therapy for an inherited muscular wasting disease, according to researchers at the University of Oregon and the University of Rochester School of Medicine and Dentistry in New York.
Using imaging mass spectrometry, researchers at the University of California, San Diego have developed tools that will enable scientists to visualize how different cell populations of cells communicate.
The loss of a gene through deletion of genetic material on chromosome 15 is associated with significant abnormalities in learning and behavior, said a consortium of researchers led by Baylor College of Medicine.
Micromet recently signed two important agreements, one buying out MedImmune's development rights for blinatumomab and the second a deal to develop an anti-carcinoma antibody for sanofi-aventis.
Enzon Pharmaceuticals Inc. is selling most of its business to Italian drugmaker sigma-tau Group and will focus on its experimental cancer drugs and technologies.
Gloucester Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) approved ISTODAX (romidepsin) for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.
Biotechnology company Halozyme Therapeutics Inc. reported a bigger third-quarter loss, as it started clinical trials of a fast-acting insulin during the period.